Singapore: Samsung BioLogics, a full-service biopharmaceutical contract development and cGMP manufacturing organization, has appointed Mr Jeremy M Caudill as vice president of Global Business Development. In his new role, Mr Caudill has relocated to Korea to join the Samsung BioLogics team and has global responsibilities for all business development and related activities.

Dr Tae-Han Kim, CEO of Samsung BioLogics, says: "Jeremy brings an exceptional track record of business development in the biopharmaceutical market combined with an extensive network of senior level decision makers. He is an industry leader and brings to Samsung BioLogics an impressive background including broad international experience in business development, which will support us in selling the services of our state-of-the-art 30,000 L plant in Songdo, Korea."

Mr Caudill has over 15 years of experience in the biopharmaceutical industry.

He joins Samsung BioLogics from Oncobiologics, where he served most recently as vice president, Strategic Business Development. He also held positions at DSM Biologics where he was Global Vice President of Sales, Marketing and Business Development; Lonza and Sigma-Aldrich.